Application of active component in preparation of macrophage proliferation inhibition drug

By screening the active ingredients in Reyanning compound and inhibiting the PI3K/AKT signaling pathway and NF-κB transcription, the problem of unclear material basis of Reyanning compound in the treatment of bacterial pneumonia was solved, and effective antibacterial and anti-inflammatory effects on bacterial pneumonia were achieved.

CN119033760APending Publication Date: 2024-11-29TSING HUA DE REN XIAN HAPPINESS PHARMA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411206991.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The material basis of the existing Reyanning compound is unclear, there is a lack of effective treatment options for bacterial pneumonia, and the application of traditional Chinese medicine compound in inhibiting the proliferation of RAW 264.7 cells has not been fully explored.

Method used

A drug target database was constructed using network pharmacology to screen active ingredients in Reyanning compound, such as luteolin, apigenin, emodin, and baicalin. These ingredients exert anti-inflammatory effects by inhibiting the PI3K/AKT signaling pathway and NF-κB transcription. A drug formulation was prepared to inhibit the proliferation of RAW 264.7 cells and to inhibit Gram-positive and Gram-negative bacteria.

Benefits of technology

The main components of Reyanning Compound show significant antibacterial and bactericidal activity against pathogens causing bacterial pneumonia, especially against Gram-positive bacteria. It can reduce lung inflammation and inhibit the proliferation of RAW 264.7 cells, providing an effective treatment for bacterial pneumonia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033760A_ABST
    Figure CN119033760A_ABST
Patent Text Reader

Abstract

The invention provides an application of an active component in preparation of a reagent for inhibiting RAW 264.7 cell proliferation. The active component is selected from at least one of luteolin, apigenin, emodin and wogonin, or pharmaceutically acceptable salts thereof. The luteolin, the apigenin, the emodin and the wogonin provided by the invention can be used as RAW 264.7 cell inhibitors to be added into a culture medium for culturing or inhibiting RAW 264.7 cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of cell culture, and in particular relates to the application of an active ingredient in the preparation of a reagent for inhibiting the proliferation of RAW 264.7 cells. Background Art

[0002] Raw264.7 mouse mononuclear macrophage leukemia cells were established by W.C. Raschke of the Salk Institute in California in the ascites of male BAB / 14 mice induced by intraperitoneal injection of A-MuLV (Abelson murine leukemia virus) and are one of the most common inflammatory cell models. They are widely used in models such as acute lung injury and rheumatoid arthritis; LPS (200ng / ml) can induce this cell to differentiate into M1 and produce inflammatory factors for 12 hours, and 10ng / ml IL-4 can induce RAW264.7 cells for 12 hours to produce M2 cells.

[0003] Bacterial pneumonia is the infectious disease with the highest proportion of pneumonia. In terms of clinical manifestations, patients mainly present with symptoms such as fever, cough, sputum congestion, dyspnea and lung rales. Common pathogens include Streptococcus pneumoniae, Staphylococcus aureus and Klebsiella pneumoniae. According to its pathogenesis and symptoms, Chinese medicine classifies it as "pneumonia wheezing". Professor Wang Lie, a master of Chinese medicine, proposed the "heat toxin" theory, pointing out that "heat toxin" is the main cause of bacterial pneumonia, providing a new idea for the treatment of bacterial pneumonia. Reyanning mixture is a traditional Chinese medicine compound formula with the effect of clearing heat and detoxification. It combines the essence of multiple Chinese medicinal materials such as dandelion, Polygonum cuspidatum, Patrinia scabra and Scutellaria barbata. It is an ideal choice for the treatment of exogenous wind-heat, internal depression and fire, and cough with yellow sputum. Modern medical research has found that Reyanning mixture combined with antibiotics has an anti-methicillin-resistant Staphylococcus aureus effect, and main ingredients such as dandelion also have anti-infection effects. However, the material basis of this compound is unclear, and there are few reports on its use in the treatment of bacterial pneumonia.

[0004] The present invention adopts network pharmacology method to construct drug target database and disease target database, and obtains 49 targets by taking intersection. GO and KEGG enrichment analysis are used to analyze and identify the screened active ingredients. It provides experimental basis for the clinical treatment of bacterial pneumonia with Reyanning mixture, and provides ideas for the development and innovative application of traditional Chinese medicine compound. Summary of the invention

[0005] In view of the problems existing in the prior art, the object of the present invention is to provide an application of an active ingredient in the preparation of a reagent for inhibiting the proliferation of RAW264.7 cells.

[0006] The objective of the present invention is achieved through the following technical solutions: In a first aspect, the present invention provides a use of an active ingredient in preparing a reagent for inhibiting the proliferation of RAW 264.7 cells, wherein the active ingredient is selected from at least one of luteolin, apigenin, rhamnolide and wogonin, or a pharmaceutically acceptable salt thereof.

[0007] In a second aspect, the present invention provides a pharmaceutical preparation comprising the above-mentioned active ingredient, or at least one pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0008] In some embodiments of the present invention, the pharmaceutical preparation comprises 30-90 parts of luteolin, 30-90 parts of apigenin, 30-90 parts of emodin and 30-90 parts of wogonin, in parts by weight.

[0009] The third aspect of the present invention provides the use of the above-mentioned pharmaceutical preparation in the preparation of an antibacterial drug, wherein the antibacterial drug is used to inhibit Gram-positive bacteria or Gram-negative bacteria.

[0010] Preferably, the Gram-positive bacteria is selected from Staphylococcus aureus, MRSA or Streptococcus pneumoniae.

[0011] Preferably, the Gram-negative bacteria are selected from Escherichia coli, Klebsiella pneumoniae or Pseudomonas aeruginosa.

[0012] In a fourth aspect, the present invention provides a culture medium comprising the above-mentioned active ingredients, DMEM high-glucose culture medium, penicillin-streptomycin double antibody and fetal bovine serum.

[0013] Preferably, in terms of mass ratio, the ratio of penicillin-streptomycin dual antibody to DMEM high-glucose medium is 1:50, and the ratio of fetal bovine serum to DMEM high-glucose medium is 1:10.

[0014] Preferably, the active ingredient is first diluted with dimethyl sulfoxide to 25.6 mg / ml, then diluted with PBS buffer to a working concentration and then added to DMEM high-glucose medium.

[0015] Preferably, the working concentrations of the active ingredients are: luteolin at 30-90 μg / ml; apigenin at 30-90 μg / mL; rhein at 30-90 μg / mL; and wogonin at 30-90 μg / mL.

[0016] In a fifth aspect, the present invention provides a non-diagnostic and non-therapeutic method for inhibiting the proliferation of 264.7 cells in vitro, comprising preparing a culture medium containing the above-mentioned active ingredients, and inoculating the RAW 264.7 cells into the culture medium for culturing.

[0017] Compared with the prior art, the beneficial effects of the present invention are: The main ingredients of Reyanning mixture, apigenin, baicalin, rhamnolide and luteolin, have good antibacterial activity against pathogens of bacterial pneumonia (including Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa). The bactericidal effect on Gram-positive bacteria is significantly better than that on Gram-negative bacteria. It has a bactericidal effect on Streptococcus pneumoniae (D39) and Staphylococcus aureus (ATCC29213) within 10 hours, and has a significant antibacterial effect on Klebsiella pneumoniae.

[0018] In mice with bacterial pneumonia induced by Streptococcus pneumoniae (D39), the main ingredients of Reyanning mixture, apigenin, wogonin, emodin and luteolin, can dose-dependently alleviate the pathological conditions of lung infection, reduce the dry-wet ratio of lung tissue, increase the thymus index, and reduce the inflammatory response caused by infection in the body. At the same time, it can inhibit the growth of bacteria in the body and reduce the bacterial load in lung lavage fluid, with obvious antibacterial effect.

[0019] The core ingredients of Reyanning mixture, apigenin, baicalin, rhamnolide and luteolin, exert anti-inflammatory effects in vivo and inhibit the proliferation of RAW 264.7 cells by inhibiting the activation of PI3K / AKT signaling pathway and inhibiting the transcription of NF-κB.

[0020] The luteolin, apigenin, rhamnolide and wogonin provided in the embodiments of the present invention can be added to the culture medium as RAW 264.7 cell inhibitors for the cultivation or inhibition of RAW 264.7 cells.

[0021] The embodiment of the present invention provides a non-diagnostic and non-therapeutic method for inhibiting the proliferation of 264.7 cells in vitro, which can be used to inhibit 264.7 cells in vitro. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 The chemical structure, extraction flow chart and mass spectrum of apigenin; a Structure and extracted ion flow chart of apigenin; b Primary mass spectrum of apigenin; c Secondary mass spectrum of apigenin; Figure 2 The chemical structure, extraction flow chart and mass spectrum of wogonin; a The structure and extracted ion flow chart of wogonin; b The primary mass spectrum of wogonin; c The secondary mass spectrum of wogonin; Figure 3 The chemical structure, extraction flow chart and mass spectrum of rhein; a The structure and extracted ion flow chart of rhein; b The primary mass spectrum of rhein; c The secondary mass spectrum of rhein; Figure 4 The chemical structure, extraction flow chart and mass spectrum of luteolin; a The structure and extracted ion flow chart of luteolin; b The primary mass spectrum of luteolin; c The secondary mass spectrum of luteolin; Figure 5Total ion current of Reyanning mixture sample; (A) Total ion current of Reyanning mixture under positive ion mode; (B) Total ion current of Reyanning mixture under negative ion mode.

[0023] Figure 6 Compound-ingredient-target network diagram; Figure 7 Construction of target library of Reyanning Decoction in the treatment of bacterial pneumonia; (A) Volcano plot of transcriptomic analysis of GEO database; (B) Target database of Reyanning Decoction in bacterial pneumonia: (C) Intersection Venn diagram of targets of Reyanning Decoction in bacterial pneumonia.

[0024] Figure 8 Protein interaction network of Reyanning mixture in the treatment of bacterial pneumonia; Fig. 9 GO enrichment analysis of targets of Reyanning mixture in the treatment of bacterial pneumonia; Fig.10 KEGG enrichment analysis of targets of Reyanning mixture in the treatment of bacterial pneumonia; Fig.11 This is a schematic diagram of the total RNA extraction process of cells in this embodiment; Fig.12 This is a flowchart of total cell protein extraction in this embodiment; Fig.13 This is a flow chart for detecting the expression of the target protein in this embodiment; Fig.14 This is a statistical chart showing the effect of different concentrations of the active ingredients of Reyanning mixture on the proliferation rate of RAW 264.7; (A) apigenin; (B) wogonin; (C) emodin; (D) luteolin. * P <0.05,** P <0.01, *** P <0.001 , n=3.

[0025] Fig.15 The cytokine expression diagram at different times of LPS cell inflammation model establishment; (A) Macrophage morphological changes; (B) Effects on the expression of cytokines TNF-α, IL-1β and IL-6 at different times of model establishment.

[0026] Fig.16 This is a statistical chart showing the inhibition of cellular inflammatory factor expression by the active ingredients of Reyanning Mixture; (A) apigenin; (B) wogonin; (C) emodin; (D) luteolin. * P <0.05,** P <0.01, *** P <0.001 vs. Model group, n=3.

[0027] Fig.17 The effects of the active ingredients of Reyanning mixture on the PI3K / Akt pathway; (A) apigenin; (B) wogonin; (C) emodin; (D) luteolin. * P <0.05,** P <0.01, *** P <0.001 vs. Model group, n=3.

[0028] Fig.18 Molecular docking diagram of apigenin, wogonin, emodin, luteolin and AKT; (A) apigenin; (B) wogonin; (C) emodin; (D) luteolin.

[0029] Fig.19 Molecular docking diagrams of apigenin, wogonin, emodin, luteolin and IκB; (A) apigenin; (B) wogonin; (C) emodin; (D) luteolin. DETAILED DESCRIPTION

[0030] The concept of the present invention will be illustrated below in conjunction with specific implementation methods.

[0031] An embodiment of the present invention provides an application of an active ingredient in preparing a reagent for inhibiting the proliferation of RAW 264.7 cells, wherein the active ingredient is selected from at least one of luteolin, apigenin, rhamnolide and wogonin, or a pharmaceutically acceptable salt thereof.

[0032] A preferred embodiment of the present invention provides a pharmaceutical preparation comprising the above-mentioned active ingredient, or at least one pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0033] In some embodiments of the present invention, the pharmaceutical preparation comprises 30-90 parts of luteolin, 30-90 parts of apigenin, 30-90 parts of emodin and 30-90 parts of wogonin, in parts by weight.

[0034] Another preferred embodiment of the present invention provides the use of the above-mentioned pharmaceutical preparation in the preparation of an antibacterial drug, wherein the antibacterial drug is used to inhibit Gram-positive bacteria or Gram-negative bacteria.

[0035] In some embodiments, the Gram-positive bacteria is selected from Staphylococcus aureus, MRSA, or Streptococcus pneumoniae.

[0036] In some embodiments, the Gram-negative bacteria is selected from Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa.

[0037] Another preferred embodiment of the present invention provides a culture medium comprising the above-mentioned active ingredients, DMEM high-glucose culture medium, penicillin-streptomycin double antibody and fetal bovine serum.

[0038] In some embodiments, the ratio of penicillin-streptomycin dual antibody to DMEM high-glucose medium is 1:50, and the ratio of fetal bovine serum to DMEM high-glucose medium is 1:10, based on the mass ratio.

[0039] In some embodiments, the active ingredient is first diluted with dimethyl sulfoxide to 25.6 mg / ml, then diluted with PBS buffer to a working concentration and then added to DMEM high glucose medium.

[0040] In some embodiments, the working concentrations of the active ingredients are: luteolin at 30-90 μg / ml; apigenin at 30-90 μg / mL; rhein at 30-90 μg / mL; and wogonin at 30-90 μg / mL.

[0041] Another preferred embodiment of the present invention provides a non-diagnostic and non-therapeutic method for inhibiting the proliferation of 264.7 cells in vitro, comprising preparing a culture medium containing the above-mentioned active ingredients, and inoculating the RAW 264.7 cells into the culture medium for culturing.

[0042] The technical solution of the present invention will be demonstrated and explained in detail through a specific experimental process below.

[0043] The effective ingredients of traditional Chinese medicine are the material basis for preventing and curing diseases. This application adopts UPLC-Q / TOF-MS technology and UNIFI analysis platform to separate and screen the chemical components of Reyanning mixture, and screen out the components with possible pharmacological activity to lay its material basis.

[0044] As a perfect combination of modern technology and traditional Chinese medicine theory, network pharmacology of Chinese medicine compound has the same purpose as the "multi-component-multi-target" concept in traditional Chinese medicine theory. This concept emphasizes that multiple components in Chinese medicine can act on multiple targets at the same time, thereby achieving a synergistic therapeutic effect. Network pharmacology technology is based on this concept. By constructing a complex interaction network, it systematically studies the potential components in Chinese medicine and their interactions with biological molecules, and deeply understands the material basis of the efficacy of Chinese medicine. This application will conduct a preliminary discussion on the mechanism of Reyanning mixture in the treatment of bacterial pneumonia by combining the results of in vivo and in vitro experimental studies.

[0045] 1.1 Materials 1.1.1 Experimental instruments Table 1 Instruments Instrument Name Production Company UPLC / Q-TOF-MS system (Vion IMS Qtof) Waters Corporation Electronic balance (YP20001) Shanghai Hengji Company Pipette (Research® plus) Eppendorf Spiral mixer (VORTEX-5) Haimen Qilin Bell Ultrasonic oscillator (KQ-500DE) Kunshan Ultrasonic Instrument Company 1.1.2 Experimental consumables The consumables used in the experiment are shown in the following table.

[0046] Table 2 Experimental consumables Consumables Name Production Company ACQUITY UPLC BEH C18 Waters Corporation EP tube (10 / 50 mL) Beijing Lanjieke Technology Co., Ltd. Injection vial (1.5 mL) Thermo Fisher Scientific Pipette tips (10 / 200 / 1000 / 5000 μL) Thermo Fisher Scientific 1.1.3 Drug and compound standards Table 3 Experimental compounds Drug Name Production Company Reyanning mixture (RYNM) Tsinghua Deren Xi'an Xingfu Pharmaceutical Co., Ltd. Scutellarin Chengdu Efa Biotechnology Co., Ltd. Emodin Chengdu Aifa Biological Company Chicoric acid Chengdu Efa Biotechnology Co., Ltd. Polydatin Chengdu Aifa Biological Company

[0047] (1) Preparation of test solution: Measure 10 μL of the original solution of Reyanning mixture and add it to 10 mL of acetonitrile solvent (acetonitrile: water = 1:1), mix well, centrifuge, and aspirate 900 μL of the supernatant for sample loading.

[0048] (2) Preparation of mixed standard solution: accurately weigh 1 mg each of the reference substances polydatin, rhamnolide, chicoric acid, and baicalin, place them in different centrifuge tubes, add 1 mL of acetonitrile and shake to dissolve; take 125 μL of each and add 500 μL of acetonitrile to dilute, centrifuge at 10,000 rpm for 10 min; take 20 μL of the supernatant and add it to 1 mL of pure water, centrifuge at 10,000 rpm for 10 min, take 900 μL and add it to a liquid phase vial to prepare a mixed standard solution, and load it onto the machine.

[0049] (3) Liquid chromatography conditions: The chromatographic column used in this experiment was Waters ACQUITY UP-LC BEH C 18 (100 mm×4.6 mm, 1.7 μm); 1 mL / L formic acid aqueous solution (A)-acetonitrile (B) was used as the mobile phase for gradient elution. The HPLC elution gradient is shown in Table 4.

[0050] Table 4

[0051] (4) Mass spectrometry conditions: positive ion mode (ESi+) and negative ion mode (ESi-) were used for detection. The scanning time was 0.2s and the scanning range was 50m / z-2000Da. Positive ion mode: capillary voltage 2.00kV, ion source temperature 120℃, desolvation temperature 500℃, desolvation gas nitrogen (N2) flow rate 1000L / h, cone gas flow rate 50L / h, and leucine enkephalin was used as the calibration liquid. Negative ion mode: capillary voltage 2.50kV, ion source temperature 100℃, desolvation temperature 450℃, desolvation gas nitrogen (N2) flow rate 600L / h, cone gas flow rate 50L / h, and reserpine was used as the calibration liquid.

[0052] (5) Establishment of the UNIFI analysis platform for Reyanning mixture: The chemical components of Taraxacum mongolicum, Polygonum cuspidatum, Patrinia serrata, and Scutellaria barbata were collected and sorted in databases such as TCMSP, BATMAN, symmap, ETCM, and PubChem, and information on compounds that may be related to Reyanning mixture was obtained, including chemical component names, structural formulas, molecular formulas, and chemical structures. The compound structural formulas were stored in .mol ​​mode, sorted into Excel tables and put into folders, and the chemical component database of Reyanning mixture was constructed. The chemical components were uploaded to the local UNIFI analysis platform and the compounds were analyzed.

[0053] (6) Optimization of ultra-high performance liquid chromatography and mass spectrometry conditions: UNIFI platform automatically matched and screened. After optimizing the parameters, the screening settings were: Mass error (ppm) ±5, Response ≥ 2000, and [M+H] was selected for the positive ion mode. + and 2×[M+H] + , negative ion mode selects [MH] – and 2×[MH] - .

[0054] (7) Data processing and analysis: Manually check the detailed information of compound test samples and standard reference substances to ensure accurate analysis.

[0055] 1.2.2 Chemical component screening and target collection of Reyanning mixture based on material basis research The literature was combined with the chemical components screened based on UPLC-Q / TOF-MS technology in the TCMSP database, BTAMAN-TCM database, ETCM database, and SymMAP database to obtain the active ingredients of Reyanning mixture, and the corresponding targets were searched in the database. The databases were sorted and summarized to build a drug target library.

[0056] 1.2.3 Construction of the target database of Reyanning mixture on bacterial pneumonia Construction of bacterial pneumonia target library: Using "pneumonia" and "bacterial pneumonia" as keywords, access the DrugBank database, TTD database, GEO database, GeneCards database, OMIM database and PharmGkb database, and input the target names obtained from the database into the UniProt database to obtain the target gene name. Search the GEO database for direct data of "pneumonia" and "bacterial pneumonia" to obtain transcriptomics data, which are analyzed using the R tool to obtain the intersection of public database targets as the bacterial pneumonia target database.

[0057] R software processing: R software was used to intersect the bacterial pneumonia target library with the Reyanning mixture target library, draw a Venn diagram, and obtain active targets that may be effective.

[0058] The collected herbal targets and corresponding active ingredients were visualized using software, compound networks were constructed, and network topology analysis was performed.

[0059] Prepare the input file based on the intersection genes obtained from the bacterial pneumonia target library and the Reyanning mixture target library, and copy the gene names in the intersection file to the corresponding boxes in the string database. Select the "Homo Sapiens" species to obtain the constructed protein interaction network. Set the filtering conditions, delete the free nodes, and obtain a clearer protein interaction network diagram.

[0060] GO enrichment analysis: The intersection target genes obtained by screening were summarized and GO enrichment analysis was performed using the R software toolkit (P ≤ 0.01) to generate results for analysis.

[0061] KEGG enrichment analysis: The intersection target genes obtained by screening were summarized and KEGG enrichment analysis was performed using the R software toolkit (P ≤ 0.01), and the top 20 results were selected for analysis.

[0062] 1.3 Results

[0063] The optimization of ultra-high performance liquid chromatography and mass spectrometry conditions was explored, and the mobile phase was determined to be formic acid aqueous solution and acetonitrile, and the column temperature was 35°C. The addition of formic acid effectively improved the tailing of the chromatographic peak. Considering the complex composition of Reyanning mixture, positive and negative ion modes were used for scanning analysis and screening.

[0064] After high-throughput screening using the UNIFI data analysis platform, 87 chemical components were detected in Reyanning mixture, of which 8 were derived from Patrinia odoratum, 24 from Taraxacum officinale, 32 from Scutellaria barbata, and 23 from Polygonum cuspidatum. Details of the identified components are shown in Table 5, and the identification and ion flow diagram of the standard are shown in Table 6. Four of the compounds were identified by comparing the detailed information with the standard, and the compound structural formula and extracted ion flow diagram mass spectrum are shown in Figure 1-Figure 4 The total ion current diagram of Reyanning mixture is shown in Figure 5 .

[0065] Table 5 Identification table of the active ingredients of Reyanning mixture

[0066] Table 6 Identification results of standard substance of Reyanning mixture

[0067] 1.3.3 Screening of chemical components and target collection of Reyanning mixture based on material basis The chemical components contained in Reyanning mixture were identified and screened under the screening conditions of Mass error (ppm) ±5, Response ≥ 2000. A total of 42 compounds were screened out, and the detailed information is shown in Table 7. Figure 6 As shown in the figure, 244 targets were collected from 42 compound components in various databases. The chemical components of Reyanning mixture and the compound target database were used to construct a "compound-component-target" network system using Cytoscape 3.8.0 software. The network has a total of 416 nodes and 921 edges. Among them, 244 nodes represent the targets received by Reyanning mixture, 34 nodes represent the unique component targets of the four herbs, and the blue in the middle is a total of 244 drug targets. The darker the color and the larger the area of ​​the graph, the more it is associated with the drug. The periphery is the drug composition and active ingredients; different colors represent different categories of herbs.

[0068] Table 7 Screened active ingredients of Reyanning mixture

[0069] The keywords were searched in the PharmGkb database for 46 targets, in the Drugbank database for 10 targets, in the Genecards database for 2543 targets, in the TTD database for 6 targets, and in the OMIM database for 2 targets. The transcriptomic data of GSE35716, GSE40012, and GSE20346 were analyzed in the GEO database, and the control group and the experimental group were selected for analysis and comparison, resulting in 21655 targets. The intersection of the public database and the GEO database targets was used as the target database for bacterial pneumonia, such as Figure 7 (B).

[0070] The intersection of 244 targets acted by the components of the Reyanning mixture and 914 targets related to bacterial pneumonia was taken to obtain the target database of Reyanning mixture on bacterial pneumonia, and a total of 49 targets were obtained. The detailed information of the targets is shown in Table 8, and the specific information of the collected targets is shown in Figure 7 (C).

[0071] Table 8 Targets of Reyanning mixture in the treatment of bacterial pneumonia

[0072] In order to further understand the interaction relationship of Reyanning mixture with disease target proteins, the 49 intersection targets obtained were imported into the database for PPI network construction and analysis, and the discrete proteins were removed to obtain the PPI network diagram (see Figure 8 .

[0073] The PPI results were imported into Cytoscape for topological analysis, and a total of 23 key targets were obtained. After analysis, they were found to be ACE, HMOX1, SERPINE1, MPO, CCL2, IL1β, CYP3A4, ADRB2, PTGS2, ADRB1, MMP9, IL6, CFTR, IL4, BTK, CD40LG, RELA, NOS2, IL13, CYP19A1, CYP1A2, CYP1A1, and TERT (see Figure 8).

[0074] The 49 intersection targets obtained were subjected to GO enrichment analysis and KEGG enrichment analysis.

[0075] GO analysis consists of three parts: BP, CC, and MF. The biological processes that affect the biological function (BP) according to the size of the P value include: regulation of apoptotic signaling pathway, regulation of inflammatory response, response to molecule of bacterial origin, etc. Cellular components (CC) include: caveola, cytoplasmic vesicle lumen, etc. Molecular functions (MF) include: cytokine activity, transcription coactivator binding, etc., see Fig. 9 .

[0076] KEGG analysis found that it was related to IL-17 signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway and other signaling pathways. Fig.10 .

[0077] This application uses UPLC-Q / TOF-MS combined with UNIFI analysis platform to analyze and high-throughput screen the active ingredients of Reyanning mixture. UNIFI analysis has the characteristics of being targeted and can perform high-throughput screening of Chinese medicine ingredients without the need for manual spectrum interpretation. It is an indispensable technical platform for the study of Chinese medicine ingredients. Through this technical study, it was found that 87 chemical components of Reyanning mixture can be separated and identified, of which 8 chemical components are derived from Patrinia odoratum, 24 chemical components are derived from Taraxacum mongolicum, 32 chemical components are derived from Scutellaria barbata, and 23 chemical components are derived from Polygonum cuspidatum.

[0078] In order to further determine the mechanism of action of Reyanning mixture in the treatment of bacterial pneumonia, we predicted its anti-infection mechanism by joint network pharmacology. It is known that the main ingredients of Reyanning mixture are dandelion, Polygonum cuspidatum, Patrinia scabra and Scutellaria barbata. The above Chinese medicine ingredients were collected from 6 databases, and 42 effective ingredients were obtained. At the same time, the corresponding disease target genes were obtained from the database based on "bacterial pneumonia" as the keyword. The target genes corresponding to the effective ingredients and the target genes corresponding to the disease were intersected to obtain 49 targets, and the compound network was constructed to analyze the relationship between the active ingredients and the targets. Then, a protein interaction network between the target genes was constructed to understand the relationship between proteins, and the obtained network was analyzed. The mechanism of action of Reyanning mixture in the treatment of bacterial pneumonia was deeply explored through GO enrichment analysis. The analysis results showed that Reyanning mixture can regulate a series of important biological processes, including the regulation of apoptotic signaling pathways and the regulation of inflammatory responses. These regulatory effects not only reveal the pharmacological activity of Reyanning mixture in the treatment of bacterial pneumonia, but also provide strong theoretical support for our understanding of its efficacy. In the process of dealing with bacterial invasion, Reyanning mixture can effectively regulate the reaction related to bacteria-derived molecules, thereby blocking further bacterial invasion. At the same time, it can also regulate the inflammatory response, alleviate the symptoms of lung inflammation, and promote recovery from the disease. When performing KEGG enrichment analysis, the pathway results found that the PI3K / AKT pathway plays a key role in the treatment of inflammation.

[0079] The PI3K / AKT pathway works through protein phosphorylation. AKT ensures cell survival by mediating cell growth factors and inactivating pro-apoptotic proteins. Under certain conditions, IKK kinase plays an indirect role in the activation of transcription factor NF-κB after being phosphorylated by AKT. The relationship between AKT and NF-κB is actually complicated. Studies have shown that AKT can promote the phosphorylation of NF-κB subunits by inhibiting the degradation of IκB protein. At the same time, when AKT function in cells is enhanced, the transcriptional activity of NF-κB is upregulated, and the use of AKT inhibitors will interfere with the upregulation of NF-κB. These studies show that the activation of the NF-κB pathway requires the participation of upstream pathway genes. Recent studies have also found that NF-κB can phosphorylate the IKKα complex, and the IKK complex can act on IκB inhibitory proteins and phosphorylate NF-κB / P65 proteins, playing a role in signal transmission between AKT and NF-κB. In this study, Reyanning mixture activated and inhibited the phosphorylation of AKT in the pathway, preventing the pathway from being activated. It also reduced the level of IκB phosphorylation and promoted the reduction of NF-κB activation level, thereby achieving anti-inflammatory effects.

[0080] The present application example study found that Reyanning mixture has anti-infective activity in vivo and in vitro. The above determined the material basis of Reyanning mixture and predicted the possible target of Reyanning mixture in the treatment of bacterial pneumonia. However, the target and mechanism of action of Reyanning mixture in the treatment of bacterial pneumonia still need to be studied.

[0081] This section will conduct a preliminary discussion on the mechanism of Reyanning mixture in treating bacterial pneumonia through cell experiments and molecular biology techniques combined with the above research results.

[0082] 2.1 Materials

[0083] 2.1.1 Main databases and software Table 9 Database software Database name Website UniProt http: / / www.uniprot.org / Discovery Studio2019 Version19.1.0.18287 Autodock Version4.2.6 PDB https: / / www.rcsb.org / PyMOL Version2.5 2.1.2 Experimental reagents Table 10 Experimental reagents Reagent name Reagent Source Reyanning mixture Tsinghua Deren Xi'an Xingfu Pharmaceutical Co., Ltd. Chicoric acid Chengdu Aifa Biological Company Trizol Thermo Fisher Scientific Wogonin Chengdu Efa Biotechnology Co., Ltd. Paeoniflorin Chengdu Aifa Biological Company Imipenem Dalian Meilun Biological Company Apigenin Chengdu Efa Biotechnology Co., Ltd. RT-PCR primers Shanghai Sangon Biotech Caffeic acid Chengdu Aifa Biological Company Meropenem Dalian Meilun Biological Company FBS Fetal Bovine Serum GeminiBio Rhein Chengdu Aifa Biological Company Super plus qPCR RT Shanghai Diyi Biological Company Polydatin Chengdu Aifa Biological Company SYBR Mix Shanghai Diyi Biological Company Lysis buffer Blue Sky Protein phosphatase inhibitor cocktail Suzhou New Saimei Biotechnology 5× Protein Loading Buffer Suzhou New Saimei Biotechnology Western Blot Regeneration Solution / Antibody Stripping Solution Suzhou New Saimei Biotechnology GAPDH Wuhan Mitaka Co., Ltd. Anti-IKB α Abcam, USA BCA Protein Concentration Assay Kit Thermo Fisher Scientific Protein ladder Beijing Juhemei Company Goat anti-rabbit IgG Proteintech Goat anti-mouse IgG Xi'an Zhuangzhi Biological Company Ultra-sensitive Luminescence Detection Kit Xi'an Zhuangzhi Company Anti-IKB α (phospho S36) Abcam, USA Anti-AKT (Ser473) Wuhan Mitaka Co., Ltd. Anti-AKT (phosphor S473) Abcam, USA Macrophages Air Force Medical University 2.1.3 Experimental instruments Table 11 Instruments used in the experiment Instrument Name Specifications Production Company Constant temperature shaker ZHWY 103D Shanghai Zhicheng Instrument Co., Ltd. UV spectrophotometer P330 IMPLEN Corporation Biological Safety Cabinets HFsafe-1200 Shanghai Lishen Company Optical Microscope CX21 Olympus ELISA reader ELx800 BioTek Corporation Electrophoresis Apparatus EPS 600 Shanghai Tianneng Technology Co., Ltd. Real-time quantitative PCR instrument Mx3005P Agilent Technologies Inc. Cell culture incubator CCL-1708-8 German ESCO Company Chemiluminescent gel imager 4800 Multi Shanghai Tianneng Technology Co., Ltd. 2.1.4 Preparation of commonly used reagents and drugs (1) MH broth (MHB): Weigh 16.0 g of MHB powder and 1000 mL of pure water, pour into a conical flask, stir with a glass rod until completely dissolved, cover and place in an autoclave for sterilization for 15 min. After cooling, place in a 4°C refrigerator for later use.

[0084] (2) Lysogeny luteolin (LB): Weigh 15 g LB powder and pour 600 mL pure water into a conical flask. Stir with a glass rod until completely dissolved. Cover the flask and sterilize it in an autoclave for 15 min. After cooling, store it in a 4°C refrigerator for later use.

[0085] (3) MH agar medium (MHA): Weigh 25 g of MHB powder, 10 g of agar powder and 1000 mL of pure water into a conical flask, stir with a glass rod to completely dissolve, cover and sterilize in an autoclave for 15 min. After cooling to 55°C-65°C, pour into a sterilized culture dish in a clean bench to a thickness of about 4 mm. After solidification, turn it upside down and store it in a constant temperature incubator.

[0086] (4) TSB broth (TSB): Weigh 12.5 g of TSB broth powder and 500 mL of ultrapure deionized water into a conical flask and stir with a glass rod to completely dissolve it. Cover the flask and sterilize it in an autoclave for 15 min. After cooling, store it in a 4°C refrigerator for later use.

[0087] (5) TSA medium (TSA): Weigh 30 g TSB powder, 10 g agar powder and 1000 mL pure water into a conical flask, stir with a glass rod to completely dissolve, cover and sterilize in an autoclave for 15 min. After cooling to 55°C-65°C, pour into a sterilized culture dish in a clean bench to a thickness of about 4 mm. After solidification, turn it upside down and store it in a constant temperature incubator.

[0088] (6) THY medium (Todd Hewitt east extract): Weigh 36.4 g THB powder and 5 g yeast powder, pour into a conical flask, add 1 L of pure water, stir evenly with a glass rod to completely dissolve, cover and sterilize in an autoclave for 15 min, wait for cooling to 40°C-50°C, add 5 mL of polymyxin E and nalidixic acid each in a clean bench, and store in a 4°C refrigerator after cooling.

[0089] (7) Control drug solution: Weigh 2.56 mg of oxacillin powder and 2.56 mg of ceftazidime powder, and add 100 μL of DMSO solution to each of the two solutions in an EP tube. Shake thoroughly to dissolve the solution to prepare a stock solution with a compound concentration of 25.6 mg / mL. The stock solution can be diluted to a concentration of 1024 μg / mL and placed in a 4°C refrigerator for later use.

[0090] (8) Sterile PBS (Phosphate Buffered Saline) buffer: According to the instructions, add 40 g of PBS instant premixed granules to 1 L of deionized water in a conical flask and allow to fully dissolve. Measure 500 mL of the prepared PBS solution, sterilize it under high pressure for 20 min, and store it in a refrigerator at 4°C.

[0091] (9) Apigenin: The standard substance was dissolved in DMSO to prepare a stock solution with a concentration of 25.6 mg / mL. 40 μL was taken and added to 960 μL complete cell culture medium to prepare a working solution with a concentration of 1024 μg / mL. The remaining stock solution was stored in a -80°C refrigerator. The drug concentrations were adjusted to 5 μg / mL, 10 μg / mL, and 15 μg / mL. Similarly, wogonin, rhamnolide, and luteolin solutions were prepared and diluted to the working concentrations.

[0092] (10) WB electrophoresis buffer: Take 1 packet of MOPS-SDS Running Buffer powder and dissolve it in 1 L of double distilled water according to the instructions. Stir with a glass rod and store at room temperature until used.

[0093] (11) WB transfer buffer: Dissolve 1 packet of transfer buffer powder in 700 mL of double distilled water. Stir well with a glass rod. Add 200 mL of methanol, mix well, and precool at 4°C for later use.

[0094] (12) TBST solution: Dissolve 1 packet of TBS powder in 2 L of double distilled water. Stir well with a glass rod. Add 2 mL of Tween-20, mix well, and precool at 4°C for later use.

[0095] 2.2 Experimental methods 2.2.1 Evaluation of in vitro antibacterial activity of active ingredients against various pathogenic bacteria by broth microdilution method (1) Preparation of bacterial solution: The Streptococcus pneumoniae (D39) used in the experiment was obtained from the Pathogen and Microbiology Research Group of the Basic Medical College of the Air Force Medical University.

[0096] (2) Sample addition: Take a 96-well plate, pipette 100 μL of MHB (or THY) medium into the plate, pipette 100 μL of the drug solution (positive control group) with a concentration of 1024 μg / mL, dilute horizontally to the 10th well, and discard the last 100 μL of the liquid. 6 100 μL of CFU / mL bacterial solution was pipetted into each well using a spray gun, and meropenem and imipenem were used as drug controls. Because the active ingredients used in the experiment had color interference after dissolution, 100 μL MHB was used instead of the bacterial solution as the color control group of the active ingredients to reduce the error caused by color on the results.

[0097] (3) Result judgment: Place the 96-well plate with the sample in an incubator and incubate for 17-22 hours. Measure its OD value with a microplate reader and subtract the absorbance value of the compound itself. The concentration corresponding to the wells with no obvious difference or small difference is the MIC value of this compound or drug. At the same time, determine whether the well plate is contaminated by checking whether the liquid in the wells of the culture medium is clear. Observe whether the MIC value of the positive drug group is within the quality control range.

[0098] 2.2.2 Macrophage culture (1) Cell recovery: Take out the cells from liquid nitrogen and place them in a 37°C water bath to dissolve them quickly. Pipette the liquid in the cryotube into a centrifuge tube, centrifuge for 5 minutes, discard the supernatant, add serum-containing DMEM culture medium to suspend, and plant in a cell bottle. Observe the cell state under a microscope and place in a constant temperature incubator.

[0099] (2) Cell cryopreservation: When the cells are observed to be almost full in the culture bottle under a microscope, cryopreservation is carried out in time. Rinse with PBS, collect the cells by blowing and centrifugation, add cell freezing solution after centrifugation, and store at -80℃.

[0100] (3) Cell passaging: When the cells are observed to be almost full in the culture flask under a microscope, pass the cells in time. Discard the original culture medium and rinse with PBS. Blow the cells with the culture medium in the cell flask to form a cell suspension, and then add it to two new culture flasks.

[0101] (4) Cell counting: Wash the cells with PBS, centrifuge, add culture medium, mix well by pipetting, take 10 µL of cell suspension, add it to the coverslip, and ensure that it penetrates into the coverslip. Find the counting area under the microscope and start counting. Prepare the required cell concentration based on the calculation results of the cell count.

[0102] 2.2.3 Effects of four active ingredients on the proliferation rate of RAW 264.7 cells determined by CCK-8 Cell inoculation: Digest by pipetting, collect and centrifuge, count after suspension, and adjust the cell concentration to 5×10 3 Add 100 μL per well and incubate overnight.

[0103] Preparation of drug solution: adjust the concentration gradient to 0, 5, 10, 15, 30, 60, 90 μg / mL according to the preparation method in 4.1.4 of this application and store at -20℃.

[0104] Drug administration: 96-well plates were divided into groups, 100 μL of sample drug solution with concentrations of 0, 5, 10, 15, 30, and 60 μg / mL were added, 6 replicate wells were set up, the edges were sealed with PBS, and the plates were placed in an incubator for 24 h.

[0105] CCK-8 assay: After culturing for 24 h, remove the culture medium in the well plate, add high-glucose culture medium containing CCK-8 at a ratio of 1:10, incubate for 2 h in the dark, and detect the absorbance at OD490nm. Calculate the relative cell proliferation rate.

[0106] 2.2.4 LPS stimulation modeling time 1 μg / mL was selected as the LPS modeling concentration. After the cells adhered to the wall, LPS was added and cultured in the dark for 0, 2, 4, 6, and 8 h. RNA was extracted and the real-time fluorescence quantitative technology was used to detect the expression of TNF-α, IL-6, and IL-1β to determine the LPS stimulation modeling time.

[0107] 2.2.5 Grouping and treatment of experimental cells In the molecular biology experiment to explore the mechanism of PI3K / AKT signaling pathway, the cells were divided into control group, model group, low, medium and high concentration groups of active ingredients, where the corresponding concentrations of low, medium and high concentration groups of active ingredients were 5 μg / mL, 10 μg / mL and 15 μg / mL. When the cells were cultured to a good growth state, the medium was changed, 1 mL of complete culture medium was added to the blank group, and 1 μg / ml LPS was added to the other experimental groups for stimulation for 4 h. Under the microscope, it can be seen that the macrophages grew tentacles, indicating that the model was successfully established. At the same time, the culture medium was removed and low, medium and high concentrations of active ingredients were given for treatment.

[0108] 2.2.6 RT-PCR verification of the effects of potential active ingredients on cellular inflammatory factor levels (1) Sample preparation: For the preliminary sample preparation grouping and specific operations, see 2.2.5 of this application.

[0109] (2) Extraction of total RNA from cells: Flow chart as shown below Fig.11 All samples were kept on ice, and total RNA was quantified using a UV spectrophotometer after extraction.

[0110] (3) RNA reverse transcription: Establish the reaction system according to the instructions and prepare the liquid in the kit in two steps. The first step is to remove gDNA, add RNA template, and prepare a 10 μL system; the second step is to use the reverse transcription reagent based on the previous step and prepare a 20 μL system. After the reverse transcription reaction is completed on the PCR instrument, store it at -80℃.

[0111] (4) RT PCR: The reference system of each component was prepared on ice. The system is shown in Table 12: Table 12 Reference system of each component Component name Dosage 2× qPCR SmArt Mix (SYBR Green) 10 μL Forward Primer (10 μM) 0.4 μL Reverse Primer (10 μM) 0.4 μL cDNA Template 0.8 μL Sterile ultrapure water To 20 μL After completion, add the solution to 8 tube strips and perform fluorescence quantitative PCR reaction on the RT-PCR instrument. Set the parameters according to the instructions, including pre-denaturation, denaturation, annealing, extension and melting curve steps.

[0112] (5) After the reaction is completed, observe and save the amplification curve and melting curve of each gene. Finally, according to the measured Ct value, use the relative quantitative method (2 -ΔΔCt ) Calculate the expression level of the target gene compared with the internal reference gene.

[0113] (6) Primer design: Check GeneBank to obtain the gene sequences of inflammatory factors TNF-α, IL-6 and IL-1β, design gene primers, and after synthesis by the company, conduct preliminary experiments to ensure the availability of primers. The primers can be stored in a -20℃ refrigerator for future use. (See Table 13 for details) Table 13 Primer sequences Gene Primer sequence (5'-3') β-actin Forward GTGACGTTGACATCCGTAAAGA Reverse GCCGGACTCATCGTACTCC TNF-α Forward GACGTGGAACTGGCAGAAGAG Reverse TTGGTGGTTTGTGAGTGTGAG IL-6 Forward CCACCTCACAAGTCGGAGGCTTA Reverse GCAAGTGCATCATCGTTGTTCATAC IL-1β Forward TGAAATGCCACCTTTTGACAG Reverse CCACAGCCACAA TGAGTGATAC 2.2.7 WB verification of the effects of potential active ingredients on cell signaling pathways Sample preparation: For the preliminary sample preparation grouping and specific operations, please refer to 2.2.5 of this application.

[0114] Total cell protein extraction: Extraction flow chart as shown below Fig.12 As shown, the entire extraction process was performed on ice.

[0115] BCA quantification: Prepare AB reaction solution according to the BCA kit and use it immediately. Take a 96-well plate, use a gun to draw 200μL of AB reaction solution and add it to the well plate, draw 10μL of standard and 10μL of sample and add them to the well plate respectively, set up 3 replicates, and incubate for 0.5h. Measure the well plate at OD490nm, fit the standard curve, and calculate the total protein concentration. At the same time, mix the sample with the loading buffer in proportion, boil it in a boiling water bath for 8min, and store it at -80℃.

[0116] Detection of target protein expression: This part is described in a flowchart as follows Fig.13 After ECL chemiluminescence, take pictures and use Image J software for grayscale quantitative statistical analysis. After luminescence, wash the membrane with TBST. Add antibody stripping solution for 10 min and wash the membrane with TBST. Block with skim milk, re-block the primary antibody, block the secondary antibody, luminesce, and detect the expression of other proteins.

[0117] 2.2.8 Molecular docking The WB results showed that there were proteins with significantly different expressions. The proteins were searched in the Uniprot database, and the protein models were downloaded from the PDB database. Molecular docking was performed using AutodockTools 1.5.6 software, and visualization analysis was performed using PyMOL and Discovery Studio software. When the binding free energy was not higher than −1.25 kcal / mol, it was considered to be effectively docked.

[0118] 2.2.9 Data Statistical Analysis and Processing GraphPad Prism software was used for statistical analysis and drawing. Each group of experiments was repeated 3 times, and data processing differences were analyzed using one-way ANOVA.

[0119] 2.3 Results 2.3.1 Evaluation of the in vitro antibacterial activity of the potential active ingredients of Reyanning mixture against pathogenic bacteria With reference to the latest edition of the pharmacopoeia and combined with experimental results, 9 active ingredients were selected. The antibacterial activity was evaluated by the microbroth dilution method. Evaluation by the performance standard of antimicrobial susceptibility testing (CLSI) found that the minimum inhibitory concentration (MIC) of rhubarb against Staphylococcus aureus (ATCC29213, USA300) and Streptococcus pneumoniae (D39) was 32 μg / mL, 64 μg / mL, and 128 μg / mL, respectively. The MIC of wogonin against Staphylococcus aureus (USA300), Streptococcus pneumoniae (D39), and Klebsiella pneumoniae (ATCC700603) was 32 μg / mL, 128 μg / mL, and 64 μg / mL. The MIC of luteolin against Staphylococcus aureus (ATCC29213, USA300) was 128 μg / mL. The MICs of chicoric acid, polydatin, apigenin, paeoniflorin, caffeic acid, etc. against Staphylococcus aureus (ATCC29213, USA300), Streptococcus pneumoniae (D39), Escherichia coli (ATCC25922), Klebsiella pneumoniae (ATCC700603) and Pseudomonas aeruginosa (ATCC27853) were all greater than 256 μg / mL. The specific results are shown in Table 14 and Table 15. The MIC values ​​of meropenem and imipenem as positive control drugs against the above 6 pathogens were less than 0.5 μg / mL. According to the performance standard of antimicrobial susceptibility test (CLSI), rhamnosine, wogonin and luteolin had certain antibacterial activity, and the antibacterial activity against Gram-positive bacteria was strong.

[0120] Table 14 MIC of active ingredients of Reyanning mixture against Gram-positive bacteria

[0121] Table 15 MIC of active ingredients of Reyanning mixture against Gram-negative bacteria

[0122] 2.3.2 Effects of the four active ingredients on the proliferation rate of RAW264.7 cells Before the evaluation of anti-inflammatory activity, the effects of four active ingredients (0-90 μg / mL) of luteolin, apigenin, emodin and wogonin on the proliferation rate of RAW264.7 cells were determined. The results showed that all of them had the effect of inhibiting cell activity. Luteolin significantly inhibited cell proliferation from 30 μg, with an inhibition rate of 40.7%. Apigenin had basically no effect on the proliferation of RAW264.7 cells in the concentration range of 0-30 μg / mL, with a maximum inhibition rate of 2%. The inhibition was enhanced in the concentration range of 30-90 μg / mL, with a maximum inhibition rate of 20%. Emodin had basically no effect on the proliferation of RAW264.7 cells in the concentration range of 0-15 μg / mL, with an inhibition rate of 5%. The inhibition was enhanced in the concentration range of 30-90 μg / mL, with an inhibition rate of 40%. There was no significant effect on the proliferation of RAW264.7 cells in the concentration range of 0-30 μg / mL, but it had an inhibitory effect at the highest dose, with a maximum inhibition rate of 6.2%. The experimental results are shown in Fig.14 Based on the experimental results, 5μg / mL, 10μg / mL and 15μg / mL of the active ingredient were selected as high, medium and low concentrations for modeling and drug administration screening.

[0123] 2.3.3 LPS modeling time Macrophage growth morphology: RAW 264.7 cells were photographed and observed under a microscope that the normal group of cells grew adherently, with no significant changes in morphology and no tentacles growing out. After LPS stimulation, the cell morphology changed, tentacles grew around them, and a large number of differentiations were observed, proving that the model was successfully established.

[0124] Modeling time: LPS stimulation for 0, 2, 4, 6, and 8 h was used as the modeling time gradient. Cell RNA was extracted and the secretion of inflammatory factors such as TNF-α, IL-1β, and IL-6 was detected using RT-PCR technology. Statistical analysis was performed as follows: Fig.15 The expression of inflammatory factors was the highest at 4 h, with TNF-α expression about 15 times that of the normal group, IL-1β expression about 30 times that of the normal group, and IL-6 expression about 6 times that of the normal group. 4 h was selected as the LPS modeling time.

[0125] 2.3.4 Potential active ingredients reduce the expression of inflammatory factors such as TNF-α, IL-1β, and IL-6 The previous experiments showed that 4h of LPS stimulation was the best modeling time, and the best concentrations of the active ingredients were 5μg / mL, 10μg / mL and 15μg / mL. We used RT-PCR to detect the expression of inflammatory factors after LPS stimulation. Fig.16 Compared with the control group, the levels of TNF-α, IL-1β, and IL-6 in the model group were significantly increased (P<0.01). Compared with the model group, apigenin can significantly reduce the expression of TNF-α by about 60%, IL-1β by about 80%, and IL-6 by about 80%. Wogonin can significantly reduce the expression of TNF-α, IL-1β by about 80%, and IL-6 by about 80%. Rhein can significantly reduce the expression of TNF-α by about 60%, IL-1β by about 80%, and IL-6 by about 80%. Luteolin can significantly reduce the expression of TNF-α by about 75%, IL-1β by about 90%, and IL-6 by about 90%. The above-mentioned active ingredients inhibit the expression of inflammatory factors in a concentration-dependent manner. For specific statistical analysis, see Fig.16 .

[0126] 2.3.5 Potential active ingredients affect protein phosphorylation of PI3K / AKT signaling pathway and inhibit pathway activation Based on the results of previous experiments, we conducted an inflammatory model and used WB to explore the effects of the active ingredients on the PI3K / AKT signaling pathway. Fig.17 Compared with the control group, the levels of IκBa phosphorylation and AKT phosphorylation in the model group were significantly increased, indicating that the PI3K / AKT signaling pathway was activated. Fig.17 (AD) It can be seen that apigenin, wogonin, rhamnolide and luteolin can reduce the phosphorylation levels of IκBa and AKT proteins. For detailed analysis, see Fig.17 .

[0127] 2.3.6 Molecular docking results In order to study the specific action sites and binding modes of apigenin, wogonin, emodin and luteolin in inhibiting the phosphorylation of AKT and IκB proteins, molecular docking was used for analysis.

[0128] Download the protein model of AKT, set up the active pocket, and perform semi-flexible docking with apigenin, wogonin, rhamnolide, and luteolin ( Fig.18). The results showed that the minimum free energies of apigenin, wogonin, rhamnolide and luteolin with AKT were -6.4, -6.3, -7.2 and -7.2 kcal / mol. The hydroxyl group of apigenin formed a hydrogen bond with the AKT TYR38 residue, and the π-type cation had a Pi-Cation interaction with LYS30, which may compete for the phosphate site. The hydroxyl group of wogonin formed a hydrogen bond with the AKTGLU40 residue, and the two benzene rings formed a Pi-Alkyl hydrophobic interaction with the AKT protein, which may be the active site of the AKT protein, participating in the interaction with other molecules, or participating in the interaction between subunits to form the quaternary structure of the protein. The hydroxyl group of rhamnolide formed two hydrogen bonds with AKT GLU40 and LYS39, and also had a hydrophobic interaction. The hydroxyl group of luteolin forms a hydrogen bond with the LYS8 residue of AKT, and GLU95 forms a Pi-anion force, which can induce a unique assembly structure by forming ion pairs, hydrogen bonds, halogen bonds, etc. between anions and organic building blocks. It can be seen that apigenin, wogonin, rhamnolide and luteolin inhibit the phosphorylation of AKT through different forces.

[0129] Download the protein model of IκB, set up the active pocket, remove the ligand and water molecules, and then perform semi-flexible docking with apigenin, wogonin, rhamnolide and luteolin ( Fig.19 ). The results showed that the minimum free energies of apigenin, wogonin, rhamnolide and luteolin with IκB were -7.2, -7.8, -7.7 and -7.3 kcal / mol. The hydroxyl group of apigenin formed two hydrogen bonds with IκBGLU197 and ASP308 residues, and the benzene ring formed a Pi-Sigma interaction with IκBLCU362, competing for the phosphate site and inhibiting the phosphorylation of IκB. The hydroxyl group of wogonin formed three hydrogen bonds with IκBGLU359, ARG358 and ASP309 residues, and the flavonoid nucleus formed a Pi-Sigma interaction with IκBLEU362. The hydroxyl group of rhamnolide formed three hydrogen bonds with IκBGLU395, GLU360 and ASP309 residues, and the quinone ring nucleus formed a Pi-Sigma interaction with IκBLEU362 residue. The hydroxyl group of luteolin forms two hydrogen bonds with IκBASP309 and GLY357 residues, and the benzene ring forms a Pi-Sigma effect with IκBLEU362, and also has Pi-Cation, Pi-Alkyl, and Pi-anion effects. It can be seen that apigenin, wogonin, rhamnolide, and luteolin may competitively bind to the phosphorylation site of IκB protein and inhibit the phosphorylation of IκB.

[0130] The main ingredients of Reyanning mixture, apigenin, baicalin, rhamnolide and luteolin, have good antibacterial activity against pathogens of bacterial pneumonia (including Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Pseudomonas aeruginosa). The bactericidal effect on Gram-positive bacteria is significantly better than that on Gram-negative bacteria. It has a bactericidal effect on Streptococcus pneumoniae (D39) and Staphylococcus aureus (ATCC29213) within 10 hours, and has a significant antibacterial effect on Klebsiella pneumoniae.

[0131] In mice with bacterial pneumonia induced by Streptococcus pneumoniae (D39), the main ingredients of Reyanning mixture, apigenin, wogonin, emodin and luteolin, can dose-dependently alleviate the pathological conditions of lung infection, reduce the dry-wet ratio of lung tissue, increase the thymus index, and reduce the inflammatory response caused by infection in the body. At the same time, it can inhibit the growth of bacteria in the body and reduce the bacterial load in lung lavage fluid, with obvious antibacterial effect.

[0132] The core ingredients of Reyanning mixture, apigenin, baicalin, rhamnolide and luteolin, exert anti-inflammatory effects in vivo and inhibit the proliferation of RAW 264.7 cells by inhibiting the activation of PI3K / AKT signaling pathway and inhibiting the transcription of NF-κB.

[0133] The luteolin, apigenin, rhamnolide and wogonin provided in the embodiments of the present invention can be added to the culture medium as RAW 264.7 cell inhibitors for the cultivation or inhibition of RAW 264.7 cells.

[0134] The embodiment of the present invention provides a non-diagnostic and non-therapeutic method for inhibiting the proliferation of 264.7 cells in vitro, which can be used to inhibit 264.7 cells in vitro.

[0135] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of an active ingredient in the preparation of an agent for inhibiting the proliferation of RAW 264.7 cells, wherein the active ingredient is selected from at least one of luteolin, apigenin, rhamnolide and wogonin, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical preparation, characterized in that The invention comprises the active ingredient according to claim 1, or at least one pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. Use of the pharmaceutical preparation according to claim 2 in the preparation of antibacterial drugs, characterized in that: The antibacterial drug is used to inhibit Gram-positive bacteria or Gram-negative bacteria.

4. The use according to claim 3, characterized in that: The Gram-positive bacteria are selected from Staphylococcus aureus, MRSA or Streptococcus pneumoniae.

5. The use according to claim 3, characterized in that: The Gram-negative bacteria are selected from Escherichia coli, Klebsiella pneumoniae or Pseudomonas aeruginosa.

6. A culture medium comprising the active ingredient according to claim 1, DMEM high-glucose culture medium, penicillin-streptomycin double antibody and fetal bovine serum.

7. The culture medium according to claim 4, characterized in that In terms of mass ratio, the ratio of penicillin-streptomycin dual antibody to DMEM high-glucose culture medium is 1:50, and the ratio of fetal bovine serum to DMEM high-glucose culture medium is 1:

10.

8. The culture medium according to claim 3, characterized in that The active ingredient was first diluted with DMSO (dimethyl sulfoxide) to 25.6 mg / ml, then diluted with PBS buffer to a working concentration and then added to DMEM high-glucose culture medium.

9. The culture medium according to claim 3, characterized in that The working concentrations of the active ingredients are: luteolin at 30-90 μg / ml; apigenin at 30-90 μg / mL; rhein at 30-90 μg / mL; and wogonin at 30-90 μg / mL.

10. A non-diagnostic and non-therapeutic method for inhibiting the proliferation of 264.7 cells in vitro, characterized in that: A culture medium is prepared, wherein the culture medium comprises the active ingredient according to claim 1, and the RAW 264.7 cells are inoculated into the culture medium for culture.

Citation Information

Cited By

  • Veterinary carprofen injection and preparation method thereof

    CN121533982A